Cinclus Pharma Holding AB (OSTO:CINPHA) Forward Dividend Yield %: 0.00% (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CINPHA Cinclus Pharma Holding AB OSTO:CINPHA
6 GF Score
Price kr11.94
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Forward Dividend Yield %?

Cinclus Pharma Holding AB OSTO:CINPHA -2.61% 6 Forward Dividend Yield % is 0.00% as of Jul. 25, 2026. GuruFocus rates OSTO:CINPHA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 511 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 195694.52% on this metric.

As of today (2026-07-25), the Forward Annual Dividend Yield of Cinclus Pharma Holding AB is 0.00%.

As of today (2026-07-25), the Trailing Annual Dividend Yield of Cinclus Pharma Holding AB is 0.00%.

OSTO:CINPHA's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.07
* Ranked among companies with meaningful Forward Dividend Yield % only.

Cinclus Pharma Holding AB's Dividends per Share for the three months ended in Mar. 2026 was kr0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Cinclus Pharma Holding AB  (OSTO:CINPHA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Cinclus Pharma Holding AB Forward Dividend Yield % Related Terms


OSTO:CINPHA vs ZTS, UTHR: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cinclus Pharma Holding AB Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cinclus Pharma Holding AB's Forward Dividend Yield % falls into.


OSTO:CINPHA
6GF Score
Cinclus Pharma Holding AB OSTO:CINPHA
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a Forward Dividend Yield % of 0.00% as of Jul. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 511 companies in the Drug Manufacturers industry.
Is Cinclus Pharma Holding AB's Forward Dividend Yield % too high?
Cinclus Pharma Holding AB's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 511 companies for Forward Dividend Yield %. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median Forward Dividend Yield % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.07, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Cinclus Pharma Holding AB (OSTO:CINPHA), the current Forward Dividend Yield % is 0.00% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for OSTO:CINPHA

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr11.94
Price